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The objective of the present work was to enhance the solubility and dissolution rate of the drug raloxifene 
HCl (RLX), which is poorly soluble in water. The solubility of RLX was observed to increase with 
increasing concentration of hydroxypropyl methylcellulose (HPMC E5 LV). The optimized ratio for 
preparing a solid dispersion (SD) of RLX with HPMC E5 LV using the microwave-induced fusion method 
was 1:5 w/w. Microwave energy was used to prepare SDs. HPMC E5 LV was used as a hydrophilic 
carrier to enhance the solubility and dissolution rate of RLX. After microwave treatment, the drug 
and hydrophilic polymer are fused together, and the drug is converted from the crystalline form into 
an amorphous form. This was confirmed through scanning electron microscopy (SEM), differential 
scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) studies. These results suggested that 
the microwave method is a simple and efficient method of preparing SDs. The solubility and dissolution 
rate of the SDs were increased significantly compared with pure RLX due to the surfactant and wetting 
properties of HPMC E5 LV and the formation of molecular dispersions of the drug in HPMC E5 LV. It 
was concluded that the solubility and dissolution rate of RLX are increased significantly when an SD 
of the drug is prepared using the microwave-induced fusion method.
Uniterms: Raloxifene HCl. Microwave-induced fusion method. Solid dispersion. Solubility enhancement. 
HPMC E5 LV.
O objetivo do presente trabalho foi aumentar a solubilidade e taxa de dissolução do cloridrato de 
raloxifeno (RLX), que é pouco solúvel em água. A solubilidade do RLX aumentou com o aumento da 
concentração de hidroxipropilmetilcelulose (HPMC E5 LV). A proporção otimizada para a preparação 
de uma dispersão sólida (DS) de RLX com HPMC E5 LV utilizando o método de fusão induzida por 
microondas foi de 1:5 (p/p). A energia do microondas foi usada para preparar DS. O HPMC E5 LV foi 
utilizado como veículo hidrofílico para aumentar a solubilidade e a taxa de dissolução de RLX. Após 
o tratamento por microondas, o polímero hidrofílico e o fármaco são fundidos em conjunto, sendo o 
fármaco convertido da forma cristalina para a amorfa. Confirmou-se por meio de microscopia eletrônica 
de varredura (MEV), calorimetria exploratória diferencial (DSC) e difração de raios X do pó (PXRD). 
Estes resultados sugerem que o método de microondas é simples e eficiente para a preparação de DS. 
A solubilidade e taxa de dissolução de DS foram aumentadas, significativamente, em comparação com 
RLX puro devido às propriedades tensoativas e umectantes de HPMC E5 LV e à formação de dispersões 
moleculares do fármaco em HPMC E5 LV. Concluiu-se que a solubilidade e a taxa de dissolução de 
RLX foram significativamente aumentadas quando a DS do fármaco é preparada utilizando o método 
de fusão induzida por microondas.
Unitermos: Cloridrato de raloxifeno. Método de fusão induzida por microondas. Dispersão sólida. 
Aumento da solubilidade. HPMC E5 LV.
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INTRODUCTION
Most newly formulated chemical entities have the 
disadvantage of low bioavailability because their aqueous 
solubility and dissolution rate are low (Belgamwar et al., 
2011). Improving the water solubility of drugs is one of 
the most challenging aspects of formulation development 
(Serajuddin et al., 2000; Lin et al., 2004). The drug release 
profile must also be improved as this property is crucial 
in oral drug bioavailability, particularly for drugs with 
low gastrointestinal solubility and high permeability 
(Murali Mohan Babu et al., 2002; Karanth et al., 2006; 
Tekade et al., 2010). Many approaches have been used, 
such as micronization, solubilization, complexation with 
polymers, salt formation, using prodrugs and adding 
surfactants. However, all these methods suffer from certain 
limitations (Feeley et al., 1998). Amorphous systems 
exhibit significant solubility because of their extreme 
thermodynamic properties and lower energetic barriers 
compared with the crystalline forms (Pudipeddi et al., 
2005; Belgamwar et al., 2011). The conversion of a drug 
from the crystalline state to an amorphous state is mainly 
achieved through two different methods: melting and 
solvent evaporation (Weuts et al., 2005; Nokhodchi et al., 
2007). A novel approach based on the use of microwave 
irradiation has become a recognized method (Moneghini 
et al., 2008; Tekade et al., 2010; Shinde et al., 2010).
Microwave radiation consists of electromagnetic 
waves with frequencies between those of infrared 
and radio waves, in the range 0.3–300 GHz. It passes 
through materials and causes their molecules to oscillate, 
generating heat. Microwaves, with their ability to 
penetrate any substance, allow heat to be produced at 
any point in a sample at a given time (Kappe, 2004). 
In fact, microwave radiation offers several advantages 
such as rapid volumetric heating, no overheating at the 
surface, addressable heating, energy savings, higher yields 
and lower operating costs and involves much shorter 
preparation times (Zhou et al., 2003). It has been reported 
that microwave energy can influence the crystalline 
status of a drug and that the duration of exposure plays 
an important role in converting the drug to an amorphous 
state, thus improving its dissolution rate (Papadimitriou 
et al., 2008; Tekade et al., 2010; Kumar et al., 2011; 
Mohanachandran et al., 2010; Moneghini et al., 2008).
Raloxifene (marketed as Evista by Eli Lilly and 
Company) is an oral second-generation selective estrogen 
receptor modulator (SERM) used to prevent osteoporosis 
in postmenopausal women. It is 2-(4-hydroxyphenyl)-
3-({4-[2-(piperidin-1-yl)ethoxy] phenyl}carbonyl)-1-
benzothiophen-6-ol, which has estrogenic actions on 
bone and anti-estrogenic actions on the uterus and breast. 
It is a BCS class II drug, i.e. it has low solubility and high 
permeability. But the bioavailability of raloxifene is very 
low, only 2%, due to a high first-pass metabolism in the 
liver by glucuronidation and enterohepatic cycling (Jha 
et al., 2011). So it would be advantageous to increase 
the solubility of the molecule. Raloxifene is available 
in HCl salt form as raloxifene (RLX; Rai et al., 2010; 
Jha et al., 2011). This drug is poorly absorbed from 
the gastrointestinal (GI) tract. Therefore it is important 
to enhance its aqueous solubility and dissolution rate 
compared with the oral solid dosage forms.
In this study, solid dispersions (SDs) of RLX in a 
low-viscosity grade of hydroxypropyl methylcellulose 
(HPMC E5 LV) were prepared using a microwave-induced 
fusion technique to enhance the solubility of the drug. The 
physical properties of the SDs prepared were characterized 
through differential scanning calorimetry (DSC), scanning 
electron microscopy (SEM), powder X-ray diffractometry 
(PXRD), Fourier transform infrared spectroscopy (FTIR) 
and solubility studies.
MATERIAL AND METHOD
Material
RLX was obtained as a gift sample from Zydus 
Cadila Healthcare Limited, Ahmedabad, India. HPMC 
E5 LV was gifted by Dow Chemical Company, Midland. 
Methanol and all other reagents used were of analytical 
grade.
Method
Physical mixture
Physical mixtures of RLX and HPMC E5 LV were 
prepared by mixing them in different ratios, from 1:1 to 1:6 
w/w, simply using a mortar and pestle. Ratio optimization 
was carried out using a solubility determination method.
Microwave induced fusion method
Solid dispersions with different RLX:HPMC E5 
LV ratios, from 1:1 to 1:6 w/w, were prepared using a 
microwave-induced fusion method. RLX and HPMC E5 
LV were weighed in the ratio 1:1 and mixed gently for 
5 minutes using a mortar and pestle. A fixed amount (i.e. 
2 g) of the mixture was subjected to microwave radiation 
for different durations (3, 4, 5 and 6 minutes) at a constant 
power of 590 W in a microwave reactor (CATA-2R, 
Catalyst Systems, Pune, India). Similarly, mixtures of 
other ratios (from 1:2 to 1:6 w/w) were prepared. Only 
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one beaker was placed at a time inside the microwave 
oven. The samples were exposed to microwave radiation 
for predetermined durations (3, 4, 5 and 6 minutes). Then 
the beakers containing the samples were maintained at 
room temperature for the samples to solidify. The solid 
dispersions were collected and placed in a desiccator for 
24 hours, and then the product was pulverized using a 
mortar and pestle. The pulverized powders were passed 
through an 80# sieve.
Characterization of solid dispersions
•	 Drug content
SDs equivalent to 10 mg of RLX were weighed 
and dissolved in sufficient amounts of pH 6.8 buffer in 
a 100 mL volumetric flask, and the volume was made up 
to the mark with pH 6.8 buffer. This solution was filtered 
using a 0.45 µm membrane filter, and the concentration 
of the drug present in the solution was determined using 
a UV spectrophotometer at 287 nm.
•	 Solubility study
The solubilities of RLX, the physical mixtures 
(PMs) and the SDs prepared using the microwave-
induced fusion method were determined in a pH 6.8 
phosphate buffer at 37 °C ± 0.5 °C. For each preparation, 
an equivalent of 10 mg of drug was added to 10 mL of the 
buffer in a glass vial with a cap. The vials were placed in 
a glass shaker incubator and maintained at 37 °C ± 0.5 °C 
for 24 hours. Then the solutions were filtered through a 
0.45 µm membrane filter, and the filtrates were analyzed 
using a UV spectrophotometer at 287 nm.
•	 In vitro drug dissolution study
The dissolution rates of RLX and different SDs were 
determined in 900 mL of pH 6.8 buffer at 37 °C ± 0.5 °C 
with a stirrer rotation speed of 75 rpm using the USP 
Dissolution Apparatus II (paddle type). Aliquots (5 mL) 
of the sample were withdrawn at 5, 10, 15, 30, 45, 60, 90, 
105 and 120 minutes using a pipette. The samples were 
suitably diluted and assayed spectrophotometrically at 
287 nm. Each dissolution rate test was repeated three 
times. The dissolution efficiency (DE) was selected, as a 
model-independent parameter, to evaluate the dissolution 
rate of RLX. The DE is defined as the area under the 
dissolution curve up to time t, expressed as a percentage 
of the area of the rectangle described by 100% dissolution 
in the same time. DE60 and DE120 were calculated from the 
dissolution data and used for comparison.
•	 Fourier-transformed infrared spectroscopic study
RLX, HPMC E5 LV, the PMs and the SDs were 
mixed separately with IR-grade KBr in the ratio 1:100, 
and corresponding pellets were prepared by applying a 
pressure of 10 metric tons in a hydraulic press. The pellets 
were then scanned over a range of 4000–400 cm-1 in an 
FTIR instrument (8400 S Shimadzu).
•	 Differential scanning calorimetry study
DSC curves of RLX, HPMC E5 LV, the PMs and 
the SDs were obtained using a differential scanning 
calorimeter (Mettler Toledo DSC 1 Star System, Zurich, 
Switzerland) at heating rate of 10 °C/minute from 40 °C 
to 340 °C in a nitrogen atmosphere.
•	 Powder X-ray diffraction study
PXRD patterns of RLX, HPMC E5 LV, the PMs 
and the SDs were recorded using a diffractogram (Bruker 
AXS, D8 Advance, Germany) and Cu-Kα radiation. The 
diffractograms were run at a scanning speed of 2°/minute 
and a chart speed of 2°/2 cm per 2θ.
•	 Scanning electron microscopy study
SEM photographs of RLX and the SDs were 
obtained using a scanning electron microscope (JSM 
6390LV, JEOL Model, Japan) with a 10-kV accelerating 
voltage.
•	 Statistical evaluation
All results were expressed as the mean ± S.D. 
Differences between two related parameters were 
considered statistically significant for P-values of 0.05 or 
less. The ratio optimization, solubility determination and 
dissolution efficiency results were analyzed using one 
way ANOVA.
RESULTS AND DISCUSSION
Drug content
The drug content of the SDs prepared is given in 
Table IV. The drug content of the SDs was found to be 
91.89% ± 0.30%.
Solubility study
The ratio optimization data are shown in Table 
I. These data suggest that the solubility is significantly 
enhanced in the case of the SD with an RLX:HPMC E5 
LV ratio of 1:5. Changing the ratio to 1:6 produced no 
significant enhancement in solubility. Therefore, it was 
concluded that the 1:5 ratio is optimal and was used for 
further studies. The solubility data for RLX, the PMs and 
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the SDs are provided in Table II. These data show that 
HPMC E5 LV significantly enhanced the solubility of RLX 
in SDs compared with the solubility of RLX.
In vitro drug dissolution study
In vitro dissolution profiles of RLX and the SD 
prepared using the microwave-induced fusion method 
with an exposure time of 6 minutes are shown in Figure 
1. The dissolution profiles of RLX and SDs prepared 
with exposure times of 3, 4, 5 and 6 minutes are shown 
in Figure 2. From the dissolution profiles it is seen that 
the microwave-induced fusion technique improves the 
dissolution rate of RLX to a great extent. The dissolution 
efficiencies of SDs at 60 and 120 minutes are presented in 
Table III. The maximum enhancement in the dissolution 
rate is 65.42% ± 0.39%, at 120 minutes.
TABLE I - Ratio Optimization of Raloxifene HCl to HPMC E5 LV 
Drug: Polymer Ratio
RLX:HPMC E5 LV
Solubility
(mg/mL) 
1:1 0.994 ± 0.05
1:2 1.328 ± 0.61
1:3 2.165 ± 0.18
1:4 4.740 ± 0.87*
1:5 7.081 ± 0.86*
1:6 7.961 ± 0.87
All values are Mean ± S.D, n=3, *Significant
TABLE II - Solubility study of Raloxifene HCl, physical mixture 
and solid dispersion 
Product Solubility (mg/mL)
Raloxifene HCl 0.977 ± 0.19
Physical mixture 7.081 ± 1.02*
Solid dispersion 17.237 ± 1.58*
All values are Mean ± S.D. *Significant
TABLE III - Dissolution efficiency of RLX and solid dispersions 
 
Product
Dissolution Efficiency
DE60 DE120
Raloxifene HCl (RLX) 28.92 ± 1.53 46.42 ± 2.11
Solid dispersion: MW 3min 30.87 ± 1.46 49.84 ± 2.29
Solid dispersion: MW 4min 33.42 ± 2.92 56.72 ± 2.52*
Solid dispersion: MW 5min 39.04 ± 2.71* 59.80 ± 1.25*
Solid dispersion: MW 6min 42.61 ± 1.69* 65.42 ± 2.68*
Solid dispersions prepared by the microwave (MW) induced fusion method had exposure times of 3, 4, 5 or 6 min. All values are 
Mean ± S.D, n = 3. *Significant
FIGURE 1 - Dissolution profiles of raloxifene HCl and solid 
dispersions prepared by microwave induced fusion methods. 
(a) RLX, Raloxifene HCl (b) MW 6 min SD, solid dispersions 
prepared by the microwave induced fusion method with an 
exposure time of 6 min.
FIGURE 2 - Dissolution profiles of raloxifene HCl and solid 
dispersions prepared by the microwave induced fusion method. 
RLX, Raloxifene HCl. Solid dispersions (SD) were prepared 
by the microwave (MW) induced fusion method with different 
exposure times (3, 4, 5 and 6 min).
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FTIR spectroscopic study
FTIR spectra of RLX, HPMC E5 LV, a PM and an 
SD are presented in Figure 3. The spectra of RLX exhibit 
characteristic peaks at 1642.44 cm-1 (C=O stretching), 
1596.15 cm-1 (–C–O–C– stretching), 1466.91 cm-1 (–S–
benzothiofuron), and 905.61 cm-1 (benzene ring). Any 
interaction among a drug and excipients results in the 
shifting of the peaks of the functional groups in the IR 
spectra. But the peaks of the functional groups of RLX 
were retained well in the PM as well as in the SD. These 
results indicate that no interaction occurred between the 
drug and excipients.
Differential scanning calorimetry (DSC)
DSC thermographs of RLX, HPMC E5 LV, the PM 
and the SD are presented in Figure 4. The thermograms of 
RLX and HPMC E5 LV show the respective endothermic 
peaks corresponding to their melting points, at around 
FIGURE 3 -  Fourier transformed infrared spectra of 
(a) Raloxifene HCl, (b) HPMC E5 LV (c) Physical mixture (d) 
Solid dispersions prepared by the microwave induced fusion 
method with an exposure time of 6 min.
266.44 °C and 116.75 °C. From the thermograms of 
the SD and the PM, it is observed that there is no peak 
corresponding to the melting point of the drug, suggesting 
a reduction in crystallinity and the formation of a 
molecular dispersion of RLX in the SD as well as the PM.
Powder X- ray diffraction (PXRD)
XRD spectra of RLX, HPMC E5 LV and the SD 
are presented in Figure 5. XRD studies were performed 
in conjunction with DSC to verify the reduction in 
crystallinity of the RLX within the SD. The diffraction 
spectrum of the drug sample shows distinct peaks at 2θ 
values of 12.812°, 14.47°, 15.784°, 19.153°, 22.682° and 
25.876°. All these peaks, though of relatively low intensity, 
are also observed to in the spectrum of the SD. Thus the 
drug must have been converted from the crystalline state 
to the amorphous state in the SD.
Scanning Electron Microscopy (SEM)
The SEM photomicrographs of RLX shown in 
Figure 6 show longer crystals with a very specific 
FIGURE 4 - Differential scanning calorimetry curves of 
(a) Raloxifene HCl (b) HPMC E5 LV (c) Physical mixture and 
(d) Solid dispersions prepared by the microwave induced fusion 
method with an exposure time of 6 min.
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morphology. In contrast, in the SDs, a decrease in 
crystallinity is observed due to molecular dispersion of 
RLX in the polymer matrix.
Stability Studies
Stability studies of the formulated solid dispersions 
were carried out. Various parameters such as the drug 
content and in vitro release were determined in these 
studies. There was no colour change after the studies. The 
in vitro drug release profile of the SD after 120 minutes 
is shown in Table IV. From the results, it is seen that the 
solid dispersion is stable at 40 °C/75% RH.
CONCLUSION
The novelty of this work is the generation of an 
amorphous system, using the microwave-induced technique 
that showed a remarkably increased solubility as well as in 
vitro drug dissolution. Therefore, it is concluded that the 
use of the microwave-induced fusion method is a promising 
approach to enhancing the solubility and dissolution rate 
of RLX, which is poorly soluble in water. The mechanism 
involved in enhancing the solubility and dissolution rate of 
RLX in SDs may be attributed to the surfactant and wetting 
properties of HPMC E5 LV and the formation of molecular 
dispersions of the drug in the polymer.
FIGURE 5 - Powder X-ray diffraction patterns (a) Raloxifene 
HCl, (b) HPMC E5 LV and (c) Solid dispersions prepared by 
the microwave induced fusion method with an exposure time 
of 6 min.
FIGURE 6 - Scanning electron microscopy photographs of (a) Raloxifene HCl and (b) Solid dispersions prepared by microwave 
induced fusion method with an exposure time of 6 min.
TABLE IV - Physicochemical evaluation of solid dispersion after 
stability studies 
Time (days) Drug content (%) In vitro drug release (%)
0 91.89 ± 0.70 65.42 ± 2.68
30 91.23 ± 0.63 65.01 ± 1.52
60 91.29 ± 0.85 64.97 ± 0.92
90 90.89 ± 0.42 64.67 ± 0.89
All values are Mean ± S.D., n=3
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